Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.

District Court, W.D. Texas·Decided July 19, 2022·No. 1:20-cv-00783·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

HOMELAND INSURANCE § COMPANY OF NEW YORK, § Plaintiff, § § v. § CIVIL NO. 1-20-CV-783-RP

§ CLINICAL PATHOLOGY § LABORATORIES, INC. and § SONIC HEALTHCARE USA, § Defendants.

REPORT AND RECOMMENDATION OF THE UNITED STATES MAGISTRATE JUDGE

TO: THE HONORABLE ROBERT PITMAN UNITED STATES DISTRICT JUDGE Before the Court are Defendants’ Motion for Summary Judgment (Dkt. 63), filed October 14, 2022; Homeland Insurance Company of New York’s Sealed Response to Defendants’ Motion for Summary Judgment (Dkt. 73), filed November 1, 2021; and Defendants’ Sealed Reply in Support of their Motion for Summary Judgment (Dkt. 82), filed November 9, 2021.1 On April 21, 2022, the District Court referred the Motion and related filings to the undersigned Magistrate Judge for

1 Defendant Clinical Pathology Laboratories, Inc.’s Motion to Contest Homeland’s Clawback Request and to Compel the Production of Similar Documents (Dkt. 111), filed and referred to the undersigned Magistrate Judge on July 18, 2022, is not yet ripe and will be addressed in due course. The parties have filed many of their briefs and pleadings under seal. They also have filed redacted public versions of those documents. The Court quotes no sealed documents in this Report and Recommendation, which therefore need not be sealed. The Court reminds the parties that the public has “a general right to inspect and copy public records and documents, including judicial records and documents.” Nixon v. Warner Commc’ns, Inc., 435 U.S. 589, 597 (1978)); see also Binh Hoa Le v. Exeter Fin. Corp., 990 F.3d 410, 418 (5th Cir. 2021) (“The public’s right of access to judicial proceedings is fundamental.”); U.S. v. Holy Land Found. for Relief & Dev., 624 F.3d 685, 690 (5th Cir. 2010) (explaining the “strong presumption that all trial proceedings should be subject to scrutiny by the public”) (citation omitted). 1 Report and Recommendation, pursuant to 28 U.S.C. § 636(b)(1)(B), Federal Rule of Civil Procedure 72, and Rule 1(d) of Appendix C of the Local Rules of the United States District Court for the Western District of Texas. The Court held a hearing on the Motion on June 21, 2022, and heard oral argument from the parties. I. Background Homeland Insurance Company of New York (“Homeland”)2 brings this insurance coverage

lawsuit against Clinical Pathology Laboratories, Inc. (“CPL”) and CPL’s parent company, Sonic Healthcare USA, Inc. (“Sonic USA”) (collectively, “Defendants”).3 Homeland’s Second Amended Complaint, Dkt. 56. Homeland seeks a declaration that it has no duty to reimburse Defendants for defending a number of medical negligence lawsuits filed against them in Ireland. CPL is an Austin, Texas-based provider of medical laboratory services. Dkt. 63 at 8. CPL and Sonic USA are subsidiaries of Sonic Healthcare Limited (“Sonic”), a global healthcare company headquartered in Sydney, Australia. Dkt. 56 ¶ 28. Sonic also owns Sonic Healthcare (Ireland) Limited (“Sonic Ireland”) and MedLab Pathology (“MedLab”), both which are Irish providers of medical laboratory services. Id.

A. Ireland’s CervicalCheck Program In 2008, the Irish government, through Ireland’s National Cancer Screening Service (“NCSS”), implemented CervicalCheck, a program to provide cervical screening to women aged 25 to 60. Id. ¶ 17. MedLab and Sonic Ireland contracted with NCSS to provide cervical cytology laboratory

2 Homeland is a New York insurance company with its principal place of business in Plymouth, Minnesota. Dkt. 56 ¶ 4. 3 CPL is a Texas corporation. Id. ¶ 5. Sonic USA is a Delaware corporation with its principal place of business in Austin, Texas. Id. ¶ 6. screening services for CervicalCheck from 2010 to 2014. Id. ¶ 18. CPL provided cytology services for the program from 2010 to 2013, screening pap smear slides for signs of cancer. Dkt. 63 at 8. In 2010, CervicalCheck implemented an oversight audit review program called Cancer Audit Reviews (“CARs”) to determine whether any areas of the cervical screening process could be improved to avoid misread pap smear slides. Dkt. 56 ¶ 21. Before 2016, CARs results were

considered only for educational purposes and were not disclosed to patients. Id. ¶ 26. In February 2016, however, CervicalCheck began reporting CARs results to patients’ treating physicians. Id. B. Coverage Dispute On June 30, 2013, Homeland issued a Medical Facilities and Providers Professional Liability, General Liability and Employee Benefit Liability Policy to Sonic USA and CPL for the policy period June 30, 2013 through June 30, 2014. Dkt. 63-2 (the “2014 Policy”). The 2014 Policy covered certain claims for wrongful acts and personal injury. Id. at 26. The parties renewed the 2014 Policy for the 2015-2016 period. Notably, the 2014 and 2015 Policies covered only claims made in the United States, its territories, or Canada. Dkt. 56 ¶ 40.

In August 2015, the family of a woman (“Ms. O I”) who died after developing cervical cancer filed a negligence lawsuit in Ireland against CPL, Sonic USA, and other entities, based on alleged misread pap smear slides. Id. ¶ 49. After CPL was served with the lawsuit, it filed an insurance claim with Homeland. On July 7, 2016, Homeland denied the claim because the 2014 Policy did not cover lawsuits filed in Ireland. Id. ¶ 52. Once Defendants became aware of their gap in coverage, they “sought to secure worldwide coverage from Homeland starting with the 2016-17 policy period so that if similar claims arose in the future, they would be covered.” Dkt. 63 at 9. Homeland agreed to provide such coverage. On August 30, 2016, the parties executed a Worldwide Territory Endorsement (“WTE”) (Endorsement No. 12, Policy No. MFL-004062-0616) to the 2016 Policy, which extended coverage to claims filed against Defendants “outside the United States of America,” effective June 30, 2016. Dkt. 56 at 73, 115. Homeland alleges that it agreed to the expanded coverage only after requiring Defendants to agree to certain “warranties” in a letter dated July 27, 2016, written by Stephen Shumpert, then

Free access — add to your briefcase to read the full text and ask questions with AI

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc., (W.D. Tex. 2022).

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc. (Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

RLI Insurance Co v. Maxxon Southwest Inc
108 F. App'x 194 (Fifth Circuit, 2004)
Adams v. Travelers Indemnity Co.
465 F.3d 156 (Fifth Circuit, 2006)
Turner v. Baylor Richardson Medical Center
476 F.3d 337 (Fifth Circuit, 2007)
Arismendez v. Nightingale Home Health Care, Inc.
493 F.3d 602 (Fifth Circuit, 2007)
Washburn v. Harvey
504 F.3d 505 (Fifth Circuit, 2007)
Erie Railroad v. Tompkins
304 U.S. 64 (Supreme Court, 1938)
Nixon v. Warner Communications, Inc.
435 U.S. 589 (Supreme Court, 1978)
Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
James K. Bettes v. Stonewall Insurance Company
480 F.2d 92 (Fifth Circuit, 1973)
Summers v. Harris
573 F.2d 869 (Fifth Circuit, 1978)
Bobby Battle v. U.S. Parole Commission
834 F.2d 419 (Fifth Circuit, 1987)